A Randomized Study Evaluating the Feasibility and Activity of Three Different Combination With Gemcitabine as First Line Therapy for Non Small Cell Lung Cancer

Inclusion criteria * Histologically or cytologically confirmed diagnosis of NSCLC * Patients must have a locoregionally advanced unresectable non metastatic NSCLC Stage IIIB (only N3 supraclavicular or T4 for pleural effusion) or Stage IV according to the revised International Staging System * Patients must have at least one measurable lesion * WHO Performance Status 0 or 1 * Adequate Organ Function Exclusion criteria: * Prior systemic chemotherapy or immunotherapy including neoadjuvant or adjuvant treatments * Prior radiotherapy for NSCLC * Patients with symptomatic brain metastases or with leptomeningeal disease. However, patients with symptomatic brain metastases who become asymptomatic under corticosteroids treatment can enter the study * Current peripheral neuropathy NCI grade 2